

Special Issue

Cancer-Associated Thrombosis: From Biomarkers to Diagnostic and Therapeutic Strategies to Optimize Treatment

Message from the Guest Editors

Cancer-related thromboembolism (CAT) is an epidemiologically growing disease that has a major impact on patient morbidity and mortality, as well as on economic and human resources. Interest in this issue is strong, and we need to improve our knowledge about pathophysiological mechanisms, the identification of disease markers with clinical implications, and the optimization of diagnostic and therapeutic pathways in order to improve the management of each individual patient. There are a lot of gaps in the literature, so innovation needs to be continued in this field.

This Special Issue welcomes the submission of both clinical and basic research in the form of original articles and reviews regarding pathophysiology and the molecular mechanisms of cancer-related thrombosis (pulmonary embolism, venous thrombosis, etc.), the peculiarities associated with the individual tumor site (for example, thrombotic or hemorrhagic risk), and traditional and innovative diagnostic and therapeutic approaches to improve basic knowledge and clinical management.

Guest Editors

Dr. Roberta Pancani

Pulmonary Unit, Cardiothoracic and Vascular Department, Pisa University Hospital, 56124 Pisa, Italy

Dr. Gualtiero Palareti

Arianna Anticoagulation Foundation, Bologna, Italy

Deadline for manuscript submissions

31 October 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/235775

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).